VPT:CC - Dr. Luc Mertens Head of Echocardiography at The Hospital for Sick Children Joins Ventripoint's Clinical Advisory Board
(TheNewswire)
Toronto, Ontario – TheNewswire - January 2 1 ,2024 - Ventripoint Diagnostics Ltd.(" Ventripoint " or the " Company "), ( TSXV:VPT ) ( OTC:VPTDF ) is pleased to announce Dr. LucMertens, one of Canada’s and the world’s top practitioners ofechocardiography, is joining Ventripoint’s Clinical AdvisoryBoard.
Dr. Mertens, MD, PhD, is the current Section Head ofEchocardiography at the Hospital for Sick Children in Toronto, Canada,and is also a Professor at the University of Toronto. His achievementsand expertise are globally recognized in the echocardiographycommunity.
“To have Dr. Mertens agree to advise Ventripoint onour ongoing use of artificial intelligence to image the human heartusing ultrasound is nothing less than an honour,” said VentripointCEO, Alvira Macanovic.
Ventripoint is now finalizing the next upgrade of theCompany’s patented heart-imaging A.I. technology — VMS+ — thatturns ultrasounds into MRI-quality heart images. These A.I. enhancedimages, completed in minutes at a fraction of the time and cost ofMRIs, are now being used in hospitals in Canada, the United States,the United Kingdom, and Europe.
“Dr. Mertens and the Hospital for Sick Children wereinvolved in Ventripoint’s original clinical trials for thetechnology, bringing invaluable experience and knowledge to thedevelopment of this Canadian-made technology,” added Dr. Macanovic. “I believe Dr. Mertens’ role as an advisor will help Ventripointfurther advance the use of A.I. to improve accessible heart care inthe healthcare system.”
Ventripoint’s Canadian-built technology and softwarework for patients of all ages, and scans can usually be taken withinminutes. It has great utility for infants and children with heartconditions, who often cannot be placed in an MRI because it requiressedation.
“I look forward to working with Ventripoint tofurther this Canadian technology that uses A.I. to improve thetreatment of heart patients,” said Dr. Mertens.
SickKids, which is currently using the VMS+, isexpected to be upgraded to the next version of Ventripoint’s A.I.heart-imaging technology when it becomes commercially available thisyear.
Dr. Mertens received his medical degree from theUniversity of Leuven in Belgium and trained as a PediatricCardiologist at the University of Leuven and at The Mayo Clinic inRochester, MN (USA). He worked as a paediatric cardiologist at theUniversity Hospitals in Leuven between 1998 and 2008, focusing onpaediatric echocardiography and studying cardiac function inchildren.
Dr. Mertens has also received international recognitionas the Feigenbaum Lecturer for the American Society ofEchocardiography Scientific Sessions in 2014, as well as the FoundingChair of the European Accreditation Committee for Pediatric andCongenital Echocardiography in 2004.
About Ventripoint DiagnosticsLtd.
Ventripoint has become anindustry leader in the application of AI (Artificial Intelligence) toechocardiography. Ventripoint's VMS products are powered by itsproprietary KBR technology, which is the result of a decade ofdevelopment and provides accurate volumetric cardiac measurementsequivalent to MRI. This affordable, gold-standard alternative allowscardiologists greater confidence in the management of their patients.Providing better care to patients serves as a springboard and basicstandard for all of Ventripoint's products that guide our futuredevelopments. In addition, VMS+ is versatile and can be used with allultrasound systems from any vendor supported by regulatory marketapprovals in the U.S., Europe and Canada.
For further information, pleasecontact:
Jonathan Robinson CFA
(416) 669-1001
Neither the TSX Venture Exchange nor its RegulationServices Provider (as that term is defined in the policies of the TSXVenture Exchange) accepts responsibility for the adequacy or accuracyof this news release.
Forward Looking Statements
This news release contains forward-looking statementsand forward-looking information within the meaning of applicablesecurities laws. The use of any of the words "expect","anticipate", "continue", "estimate","objective", "ongoing", "may","will", "project", "should","believe", "plans", "intends'' and similarexpressions are intended to identify forward-looking information orstatements. The forward-looking statements and information are basedon certain key expectations and assumptions made by the Company.Although the Company believes that the expectations and assumptions onwhich such forward-looking statements and information are based arereasonable, undue reliance should not be placed on the forward-lookingstatements and information because the Company can give no assurancethat they will prove to be correct.
Since forward-looking statements and informationaddress future events and conditions, by their very nature theyinvolve inherent risks and uncertainties. Actual results could differmaterially from those currently anticipated due to a number of factorsand risks. Factors which could materially affect such forward-lookinginformation are described in the risk factors inthe Company's most recent annual management's discussion and analysisthat is available on the Company's profile on SEDAR at www.sedar.com. Readers arecautioned that the foregoing list of factors is not exhaustive. Theforward-looking statements included in this news release are expresslyqualified by this cautionary statement. The forward-looking statementsand information contained in this news release are made as of the datehereof and the Company undertakes no obligation to update publicly orrevise any forward-looking statements or information, whether as aresult of new information, future events or otherwise, unless sorequired by applicable securities laws.
Copyright (c) 2024 TheNewswire - All rights reserved.